Los Angeles, March 24, 2017: Singer Beyonce Knowles used video calling app FaceTime to connect with young cancer patient Ebony Banks, after a social media campaign under the hashtag #EbobmeetsBeyonce grabbed her attention.
Beyonce surprised the teenager, who has been battling with a rare form of the disease, with a video call on Wednesday, because it has always been her lifelong dream to meet her “idol”, reports usmagazine.com.
Speaking to KHOU channel about her last wish, Banks, who is also known as Ebob, said: “She’s (Beyonce) like my everything and my idol. And if I ever met her, I would probably pass out.”
Knowles, who has five-year-old daughter Blue Ivy with her husband Jay Z and is pregnant with twins, learnt about Banks’s dream to meet her through her school friends, who started the campaign on social media. (IANS)
Health researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer.
The study, published in the journal Scientific Reports, found that testing for a specific immune biomarker allows clinicians to identify whether growths on the ovaries are cancerous or not, without the need for tests like the MRI scans or ultrasounds.
Ovarian cancer is one of the most common gynaecologic cancers, with the highest mortality rate. About 300,000 new cases are diagnosed globally each year, with an estimated 60 per cent of women dying within five years after diagnosis.
“Our new test is as accurate as the combined results of a standard blood test and ultrasound. This is especially important for women in remote or disadvantaged communities, where under-resourced hospitals may not have access to complex and expensive equipment like ultrasound machines or MRI scanners,” said study senior author
Magdalena Plebanski from the RMIT University in Australia.
“It also means patients with benign cysts identified through imaging could potentially be spared unnecessary surgeries,” Plebanski added. According to the researchers, the test could be an important diagnostic tool for assessing suspicious ovarian growths before operations.
“This study looked at women with advanced ovarian cancer, but we hope further research could explore the potential for adding this biomarker to routine diagnostic tests at earlier stages of the disease,” Plebanski said.
The study used an immune marker for inflammation (IL-6) together with cancer markers to detect epithelial ovarian cancer in blood. According to the researchers, results were validated across two separate human trial cohorts.